Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2019

Sales of the Company’s products were as follows:



	Three Months Ended March 31,
	2019							2018
($ in millions)	U.S.			Int’l		Total		U.S.		Int’l			Total
Pharmaceutical:
Oncology
Keytruda	$	1,284		$	985	$	2,269	$	838	$	626		$	1,464
Emend	63			53		117		79		46			125
Alliance revenue - Lynparza	50			29		79		24		9			33
Alliance revenue - Lenvima	50			24		74		—		—			—
Vaccines
Gardasil/Gardasil 9	362			476		838		380		280			660
ProQuad/M-M-R II/Varivax	343			153		496		312		80			392
RotaTeq	154			57		211		151		42			193
Pneumovax 23	125			59		185		112		66			179
Vaqta	29			18		47		18		18			37
Hospital Acute Care
Bridion	119			136		255		80		124			204
Noxafil	91			99		190		81		94			176
Cubicin	42			46		88		47		51			98
Invanz	14			58		72		91		60			151
Cancidas	1			60		61		3		88			91
Primaxin	—			59		59		5		67			72
Immunology
Simponi	—			208		208		—		231			231
Remicade	—			123		123		—		167			167
Neuroscience
Belsomra	24			44		67		23		31			54
Virology
Isentress/Isentress HD	108			147		255		128		152			281
Zepatier	33			81		114		—		131			131
Cardiovascular
Zetia	—			140		140		17		287			305
Vytorin	3			94		97		8		158			167
Atozet	—			94		94		—		73			73
Adempas	—			90		90		—		68			68
Diabetes
Januvia	384			440		824		465		416			880
Janumet	167			364		530		192		352			544
Women’s Health
NuvaRing	185			34		219		171		46			216
Implanon/Nexplanon	149			50		199		128		46			174
Diversified Brands
Singulair	5			186		191		6		170			175
Cozaar/Hyzaar	4			99		103		7		113			120
Nasonex	(1		)	97		96		1		121			122
Arcoxia	—			75		75		—		83			83
Follistim AQ	29			28		57		29		39			67
Other pharmaceutical ⁽¹⁾	358			782		1,140		320		867			1,186
Total Pharmaceutical segment sales	4,175			5,488		9,663		3,716		5,202			8,919
Animal Health:
Livestock	117			494		611		124		529			652
Companion Animals	177			237		414		183		229			413
Total Animal Health segment sales	294			731		1,025		307		758			1,065
Other segment sales ⁽²⁾	39			—		39		84		—			84
Total segment sales	4,508			6,219		10,727		4,107		5,960			10,068
Other ⁽³⁾	7			82		89		26		(56		)	(31		)
	$	4,515		$	6,301	$	10,816	$	4,133	$	5,904		$	10,037

U.S. plus international may not equal total due to rounding.


⁽¹⁾	Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.


⁽²⁾	Represents the non-reportable segments of Healthcare Services and Alliances.


⁽³⁾	Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales.

Consolidated sales by geographic area where derived are as follows:



	Three Months Ended March 31,
($ in millions)	2019		2018
United States	$	4,515	$	4,133
Europe, Middle East and Africa	3,103		3,191
Japan	799		737
China	746		486
Asia Pacific (other than Japan and China)	745		752
Latin America	561		532
Other	347		206
	$	10,816	$	10,037

A reconciliation of segment profits to Income before taxes is as follows:



	Three Months Ended March 31,
($ in millions)	2019			2018
Segment profits:
Pharmaceutical segment	$	6,574		$	5,939
Animal Health segment	415			413
Other segments	2			63
Total segment profits	6,991			6,415
Other profits (losses)	30			(87		)
Unallocated:
Interest income	89			85
Interest expense	(209		)	(185		)
Depreciation and amortization	(359		)	(350		)
Research and development	(1,843		)	(3,117		)
Amortization of purchase accounting adjustments	(397		)	(733		)
Restructuring costs	(153		)	(95		)
Other unallocated, net	(1,082		)	(588		)
	$	3,067		$	1,345